Ifinatamab deruxtecan

Ifinatamab deruxtecan (DS-7300a) is an ADC that binds an anti-B7-H3 antibody to the DNA topoisomerase I inhibitory anti-tumor drug DXd. Ifinatamab deruxtecan has antitumor activity[1].

Product Specifications

CAS Number

[2484870-92-8]

Product Name Alternative

DS-7300a; MABX-9001a

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ifinatamab-deruxtecan.html

Purity

99.29

Solubility

10 mM in DMSO

Smiles

[Ifinatamabderuxtecan]

References & Citations

[1]Katsumata L, et al. Ifinatamab deruxtecan (I-DXd), a novel B7-H3-targeting antibody-drug conjugate, demonstrates efficient payload delivery into tumor through target-dependent internalization. Cancer Research, 2023, 83 (7_Supplement) : 4891-4891.